Erica Horwitz
About Erica Horwitz
Erica Horwitz is the Vice President of Corporate Development and Head of M&A at Bristol Myers Squibb, with extensive experience in mergers and acquisitions, particularly in the healthcare sector.
Title
Erica Horwitz is the Vice President of Corporate Development, Head of Mergers & Acquisitions (M&A) at Bristol Myers Squibb. She is currently based in Lawrenceville, New Jersey, and has held this position since April 2021.
Education and Expertise
Erica Horwitz holds a Master of Business Administration from the Stephen M. Ross School of Business, which she completed between 2010 and 2012. She also holds a Bachelor's degree in Economics from the University of Michigan, where she studied from 2001 to 2005. Her extensive education has been foundational to her expertise in corporate development and transaction advisory services.
Professional Background
Erica Horwitz has over a decade of experience in corporate development and M&A. She joined Bristol Myers Squibb in April 2021. Prior to this, she held several roles at Barclays, including Director of M&A, Director of the Global Healthcare Group, and Vice President of the Global Healthcare Group. She has also worked at Barclays Capital as a Summer Associate and spent five years at Ernst & Young in Transaction Advisory Services as a Senior Consultant. Her career also includes a tenure at Celgene, further strengthening her background in the biopharmaceutical industry.
Corporate Experience at Bristol Myers Squibb
At Bristol Myers Squibb, Erica Horwitz serves as the Vice President of Corporate Development and Head of Mergers & Acquisitions. In this role, she has been involved in significant biopharmaceutical transactions, with a strong focus on oncology, cardiovascular, and immunology sectors. Her extensive experience in M&A and corporate development plays a pivotal role in driving the company’s strategic initiatives.
Prior Experience at Barclays
Erica Horwitz worked at Barclays for a total of approximately five years in various roles within the Global Healthcare Group. She served as Director of M&A from 2019 to 2021, Director of the Global Healthcare Group for eight months in 2019, and Vice President of the Global Healthcare Group from 2016 to 2019. Her tenure at Barclays significantly contributed to her deep understanding and expertise in healthcare transactions and M&A.